Heparin-induced thrombocytopenia: how to manage it, how to avoid it

Review published in Cleve Clin J Med (2000)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board

Research article — evidence reviewArticle reference

Evidence: Narrative reviewDesarrollo de fármacosEnsayos clínicosCaiola E · Cleveland Clinic journal of medicine, 2000

Abstract

Heparin therapy has two potential adverse effects: bleeding and heparin-induced thrombocytopenia (HIT). There are two types of HIT: type I is more common but less severe; type II occurs less frequently but involves severe thrombocytopenia and a high risk for thrombotic events. Treatment involves discontinuing heparin, allowing the platelet count to return to normal, and treating any thrombosis. Lepirudin (Refludan) is the only agent currently approved for the treatment of HIT-related thrombosis, but other agents may have a role in combination therapy. Prevention includes using low molecular weight heparin instead of unfractionated heparin and limiting unfractionated heparin therapy to less than 5 days.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Indexed MeSH termsAnticoagulantsChondroitin SulfatesDermatan SulfateDrug CombinationsEpoprostenolHeparinHeparin, Low-Molecular-WeightHeparan SulfateHirudin TherapyHirudinsHumansPlatelet Aggregation Inhibitors

Resumen

Early review of type I and type II HIT with lepirudin (Refludan) cited as the only agent then approved for HIT-related thrombosis treatment.

Por qué esto importa para la hirudoterapia

This review discusses heparin-induced thrombocytopenia management and prevention, distinguishing type I (common, mild) from type II (less frequent, severe thrombocytopenia with high thrombotic risk), and outlining treatment as heparin discontinuation, platelet count recovery, and thrombosis treatment. The abstract specifically identifies lepirudin (Refludan) as the only agent currently approved for treatment of HIT-related thrombosis, while noting other agents may have a role in combination therapy, and recommends prevention through low-molecular-weight heparin use and limiting unfractionated heparin duration. This is relevant to ASH's domain because the abstract names lepirudin (Refludan) and its approved status for HIT-related thrombosis, though the abstract itself does not identify lepirudin as hirudin-derived or mention leeches. The caveat is that the abstract offers no dosing or outcome detail specific to lepirudin, and leeches or the broader secretome are not discussed.

Citación

Heparin-induced thrombocytopenia: how to manage it, how to avoid it.

Caiola E · Cleveland Clinic journal of medicine, 2000

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug Pipeline Drug Development Direct Thrombin Inhibitors Clinical Evidence Clinical Applications Otolaryngology

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026